[Application of SF-36 scale in the survey of quality of life of occupational disease patients].

Objective: To explore the application of the Short Form of Quality of Life (SF-36) scale in the investigation of quality of life of occupational disease patients. Methods: In May 2019, SF-36 scale was used to investigate the occupational disease patients diagnosed in Hangzhou. The reliability of the scale was evaluated by Cronbach's α coefficient, and the validity of the scale was evaluated by exploratory factor analysis. Results: The Cronbach's α coefficients of PF, RP, BP, GH, VT, SF, RE and MH were 0.937, 0.977, 0.870, 0.908, 0.815, 0.701, 0.967 and 0.863 respectively, and the half reliability coefficient α=0.905. The two factor statistics representing physiological and psychological aspects were 0.870, and the approximate chi square value was 1784.337 (P<0.01) . Compared with the national norm, the scores of each dimension of quality of life of occupational disease patients were significantly lower, and the differences were statistically significant (P<0.01) ; Compared with the scores of each dimension of quality of life of pneumoconiosis patients, the scores of PF, RP and GH of occupational disease patients were significantly higher, and the differences were statistically significant (P<0.05) . Conclusion: SF-36 scale has good reliability and validity in measuring the quality of life of patients with occupational diseases, which can be used to evaluate the quality of life of patients with occupational diseases.

[Investigation and analysis of quality of life of some pneumoconiosis patients in Hangzhou].

Objective: To understand the quality of life and influencing factors of patients with pneumoconiosis, and to provide a basis for formulating targeted improvement strategies to improve the quality of life. Methods: From April to December 2018, Questionnaire survey was conducted on patients with pneumoconiosis that diagnosed in Hangzhou Hospital for the Prevention and Treatment of Occupational Disease, using self-made questionnaire and SF-36.237 valid questionnaires were used to investigate the basic conditions, health services, social assistance and quality of life of patients, and analyze the influencing factors of quality of life. Results: Hangzhou city's some pneumoconiosis patients were mostly with monthly income <3000 yuan (72.6%, 172/237) ; more patients with medical expenses of 8000 to 25000 yuan per year (60.3%, 143/237) ; The proportion of patients receiving medical assistance and work-related injury insurance was low, at 2.1% (5/237) and 23.8% (54/227) respectively. The scores of Pneumoconiosis patients in PhysicalFunction (PF) , Role-Physical (RP) , Bodily Pain (BP) , General Health (GH) , Vitality (VT) , Social Function (SF) , Role-Emotional (RE) and Mental Health (MH) were lower than the national norm (P<0.05) . The scores from high to low were BP, SF, MH, PF, VT, RE, RP and GH. There were significant differences in the quality of life scores of pneumoconiosis patients with different ages, work types, education levels and monthly income (P<0.05) . Conclusion: The quality of life of some patients with pneumoconiosis in Hangzhou is lower than that of the general population. Age, work types, and monthly income are factors influencing quality of life.

Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.

Background: CBCSG006 trial reported the superior efficacy of cisplatin plus gemcitabine (GP) regimen than paclitaxel plus gemcitabine (GT) regimen as first-line treatment of metastatic triple-negative breast cancer (mTNBC). This study focused on the updated survival data and the explorations of potential biomarkers for efficacy. Patients and methods: Germ-line mutations of homologous recombination (HR) panel, BRCA1/2 included, were evaluated in 55.9% (132/236) patients. PD-L1 expression was evaluated in 48.3% (114/236) patients. A nonparametric sliding-window subpopulation treatment effect pattern plot (STEPP) methodology was used to analyze the absolute survival benefits. All statistical tests were two-sided. Results: Median progression-free survival (PFS) was 7.73 [95% confidence interval (CI) 6.46-9.00] months for GP arm and 6.07 (95% CI 5.32-6.83) months for GT arm (P = 0.005). No significant difference in overall survival (OS) was observed. There was significant interaction between HR status and treatment for PFS and status of HR deficient significantly correlated with higher objective response rate (ORR) and longer PFS in GP arm than in GT arm (71.9% versus 38.7%, P = 0.008; 10.37 versus 4.30 months, P = 0.011). There was no significant interaction between germ-line BRCA1/2 (gBRCA1/2) status and treatment for PFS. Patients with gBRCA1/2 mutation had numerically higher ORR and prolonged PFS in GP arm than in GT arm (83.3% versus 37.5%, P = 0.086; 8.90 versus 3.20 months, P = 0.459). There was no significant interaction between PD-L1 status and treatment for PFS, and no significant differences in ORR, PFS or OS between two arms regardless of PD-L1 status. In STEPP analysis, patients with lower composite risks had more absolute benefits in PFS than those with higher composite risks. Conclusions: GP regimen has superior efficacy than GT regimen as first-line chemotherapy for mTNBC patients. Germ-line mutations of BRCA1/2 and HR panel are possible biomarkers for better performance of cisplatin-based regimens. A composite risk model was developed to guide patient selection for GP treatment in TNBC patients. Trial registration: ClinicalTrials.gov, NCT01287624.